Verition Fund Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Verition Fund Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,927	Closed	-$296K	–	3331
2022 Q2	$296K	Buy	+3,927	New	+$175K	0.01%	1741

Verition Fund Management's TPTX Position: Q3 2022 in Review

Verition Fund Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 3,927 shares — an estimated $296K sold.

Verition Fund Management first reported a position in TPTX in Q2 2022 and held it in 1 quarter. The position peaked at $296K in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Verition Fund Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Verition Fund Management sold 3,927 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $296K.
Verition Fund Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
Verition Fund Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $296K in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Verition Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.